Cargando…
Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone ma...
Autores principales: | Moseley, R. P., Davies, A. G., Richardson, R. B., Zalutsky, M., Carrell, S., Fabre, J., Slack, N., Bullimore, J., Pizer, B., Papanastassiou, V. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971477/ https://www.ncbi.nlm.nih.gov/pubmed/2223581 |
Ejemplares similares
-
Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.
por: Kemshead, J. T., et al.
Publicado: (1998) -
Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry.
por: Papanastassiou, V., et al.
Publicado: (1993) -
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
por: Jaeckle, K A, et al.
Publicado: (2001) -
Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature
por: Dumitrescu, Cristina, et al.
Publicado: (2013) -
Pre-existing anti-mouse immunoglobulin in a patient receiving 131I-murine monoclonal antibody for radioimmunolocalisation.
por: Davies, A. G., et al.
Publicado: (1986)